



In Search of the Next
Potential Breakthroughs:
A Spotlight on Our
Collaborations in Asia Pacific

It's been nearly eight years since Johnson & Johnson Innovation's presence was made in the Asia Pacific region to cultivate the best early-stage life science that aims to have a lasting and life-enhancing impact for patients and consumers in Asia and the world.

Particularly in the face of the pandemic, Asia has certainly not slowed down. On the contrary, the region was presented with more opportunities and an evolving landscape for transformative healthcare and biomedical innovation. Add to that the growing capabilities in the areas of gene and cellular therapy, future platform innovation, which includes AI enabled drug discovery, DNA encoded chemical libraries, cyclic peptides, antibody-drug conjugates, robotics, and 3D printing.

We remain steadfast on our commitment to discover, develop and deliver healthcare solutions to some of the world's largest unmet healthcare needs in oncology, infectious disease, immunology, neuroscience, vaccines, cardiovascular & metabolism, public health and MedTech; and we will continue to do this through early innovation collaborations and partnerships, strategic venture investment and incubation with entrepreneurs, start-ups, scientists and academics from across the region.

From China, Japan, South Korea, India to Singapore, we have established thousands of contacts and formed over one hundred partnerships in the life science ecosystem of the region. In the coming future, we look forward to nurturing more Asia-grown therapies with the potential to improve human health.



Dan Wang, MD, MPH, MBA

Regional Head of Johnson & Johnson Innovation, Asia Pacific

Some Examples of What We Can Achieve Together



We have built a diversified pipeline by taking a tailored approach for different innovators based on their needs. Below are some examples of what we believe to be successful collaborations we have made in life science hot spots in the region.

Pharmaceuticals



China

In June 2022, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, entered into a collaboration and license agreement with China-based biotech company Hangzhou DAC Biotechnology Co., Ltd. to apply the innovative and proprietary antibody drug conjugate (ADC) platform to Janssen's proprietary antibodies with the aim to develop novel ADC products against up to five targets. DAC Biotechnology has also received an

China

In 2016, Janssen Biotech, Inc. began a strategic partnership with HitGen in China to screen HitGen's DNA Encoded Libraries (DELs) for a series of targets in different therapeutic areas. This partnership, now going on nearly six years, has laid important foundations for the discovery of potential new therapies, including hits for targets that have been difficult to identify with a traditional library approach.



Japan

Since 2017, Janssen Pharmaceuticals, Inc. has been working with PeptiDream in Japan to leverage its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of constrained peptides against multiple targets of interest. To build on this successful collaboration, a license and technology transfer agreement was later signed between Janssen Pharmaceutica NV and PeptiDream which allowed our Janssen R&D to bring in-house PeptiDream's PDPS system to identify novel peptide-based compounds against any target of interest.

Japan

In 2021, Janssen Research and Development, LLC entered into a collaboration with the Graduate School of Agricultural and Life Sciences at The University of Tokyo with the aim to develop and validate an at-home biosensor to predict childhood food allergies. It is hoped that the non-invasive diagnostic biomarker could deliver results in less than 30 minutes and has the potential to bring about a paradigm shift in predicting symptoms for patients with food allergy, enabling appropriate intervention.



MedTech

China

In 2020, Johnson & Johnson Medical (Shanghai) Limited (JJMS) signed a collaboration agreement with Taikang (Tk.cn), a Chinese online healthcare insurance company, to develop an innovative sports injury-related insurance package. JJMS is offering Tk.cn its industrial insights, while Tk.cn designs reimbursement coverage to sports enthusiasts which aim to enable timely diagnosis and appropriate surgical treatment for patients.



South Korea

In February 2020, Ethicon Inc. and Johnson & Johnson 3D Printing entered into a collaboration with T&R Rinfah, a Korea-based 3D bioprinting company to



biofab, a Korea-based 3D bioprinting company, to develop innovative 3D bio-printed soft tissue reinforcement scaffolds (STRS), based on T&R Biofab's platform technology using polymer, in situ extracellular matrix (ECM) proteins and 3D bioprinting. These 3D bio-printed STRS have the potential to repair and replace the mechanical function of lost or damaged tissue, overcoming the challenges with surgical options in human and animal tissues.

I&K Biofab

Consumer Health



📍 China

In December 2021, Johnson and Johnson (China) Investment Ltd. entered into a research collaboration with Hangzhou Yongliu Tech to deliver a digital platform potential solution that aims to provide consumers with the ability to manage their fungal infections. The digital potential solution is intended to be used by consumers to self-evaluate their fungal infections with an image-based artificial intelligence (AI) screening tool, leverage educational modules to better understand the basic cause of fungal infections, and more proactively manage the treatment of their hand and/or foot fungal infections.

📍 South Korea

In January 2022, Johnson & Johnson Innovation, Asia Pacific, facilitated a research collaboration between Dr. Ci:Labo Co., Ltd. and Raphas Co., Ltd.—a Korean-based company specializing in microneedle patches—for the exclusive development and application of the microneedle particles under Raphas' patented Droplet Extension (DEN) technology in skin care products. Dr. Ci:Labo will work closely with Raphas with the aim to co-develop and modify the technology platform to produce individual microneedle particles which can then hopefully be dispensed in one single application to the face.



Digital Health



Insilico Medicine

📍 Hong Kong SAR

In November 2020, Janssen Pharmaceutica NV entered into a collaboration with Insilico Medicine, a resident company of JLABS @ Shanghai, with the aim to generate novel and fully patentable chemical scaffolds for difficult targets using Insilico Medicine's drug design platform for difficult targets nominated by Janssen. This will potentially lead to significant reductions in time and cost in identifying biologically active hits against selected targets.

📍 Singapore

In June 2019, Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., signed a Memorandum of Understanding with Holmusk, a JLABS @ Shanghai resident company, to explore the development of a



digital mental health strategy in China. Holmusk's digital therapeutics and deep analytics will be used with the aim to develop and implement a competitive, comprehensive solution for mental health in China, with an initial focus on depression.

Strategic Partnership



📍 China

In 2017, Johnson & Johnson Innovation announced a collaboration with the Shanghai Municipal Government, Pudong New Area Government, and Shanghai Pharma Engine Company, Ltd. to launch a new Johnson & Johnson Innovation – JLABS (JLABS) in Shanghai (JLABS @ Shanghai), China. The 4,400-square-meter facility is located in Shanghai's Zhangjiang Hi-Tech Park and was the first JLABS location established outside of North America. JLABS @ Shanghai has incubated 70 companies up until June 2022.

📍 Japan

In 2020, Janssen Biotech, Inc. entered into a strategic partnership with Takeda Pharmaceutical and Shonan Health Innovation Park (Shonan iPark) to co-organize a World Without Disease Call-for-Proposal in Japan and selected five awardees in the research areas of lung cancer, myopia, infant/child health and neuroscience. Following its success, a second grant call was launched in 2022.



📍 Taiwan SAR

Since 2017, Johnson & Johnson Innovation has been facilitating a yearly grant call in collaboration with the Industrial Technology Research Institute (ITRI), to help foster Taiwan Region's academia-industry life science ecosystem. Each year a number of proposals is selected for research collaboration agreements by providing funding and mentorship to help accelerate projects across various therapeutic areas. Research collaborations have ranged from 1 to 3 years.

How We Can Create the Right Deal for You



We leverage innovative business models and deploy a suite of capabilities to meet the diverse needs of entrepreneurs, scientists, health technology innovators and emerging companies from across the pharmaceutical, medical device and consumer health sectors.

Our 'co-creation model' allows us to create the right deal to best suit



To create the right deal to best suit the technology and the innovator with whom we are working, so that together we can have a meaningful impact on human health around the world.

Our Offering to Co-Create

Depending on where an idea is in its life cycle, integrated Johnson & Johnson Innovation teams make it easy for our collaborators and partners to tap into our broad and unique range of tools and capabilities, including:



Early Innovation Partnering & Deal-Making

[Learn More →](#)



Incubation and Acceleration with JLABS

[Learn More →](#)



Venture Investment with JJDC

[Learn More →](#)



NewCo Creation Opportunities

[Learn More →](#)



Late-Stage Partnering

[Learn More →](#)



Our Strategic Therapeutic Areas of Focus



Cardiovascular, Metabolism & Retina



Discovery, Product Development & Supply



Immunology



Data Science



Infectious Diseases & Vaccines



MedTech



Neuroscience



Consumer Health



Oncology



Integrated Healthcare Solutions




Pulmonary Hypertension



Global Public Health

Hear from some of our global therapeutic area leaders on what they are looking for in a strategic collaboration in Asia Pacific.




Making an Impact in the APAC Ecosystem Since 2014



 Regional Hub

Shanghai

Through our regional hub, based out of Shanghai, we are deeply embedded within and tightly connected to the external early innovation ecosystem around the world, with offices located in Tokyo, Seoul, Singapore and Hong Kong SAR.



Collaborations



> \$248M*

invested across Asia Pacific
from 2013 – 2021

* Innovation Center data per Jforce as of June 02, 2022



129+

total collaborations across...



5 major APAC
markets

Incubation



70

Johnson & Johnson Innovation—JLABS @ Shanghai
companies incubated



\$3.1B

raised by JLABS companies



14

of which have at least one
collaboration with a company
from the Johnson & Johnson
Family of Companies



31%

are female led



25

QuickFire Challenge
Awardees leading to...



6

collaborations with a company
from the Johnson & Johnson
Family of Companies

Equity Investment



Johnson & Johnson Innovation – JJDC has invested in several portfolio
companies across different therapeutic areas in Asia Pacific since 2014. Some
of the portfolio companies included XWPharma, Legend Biotech and
Hangzhou DAC Biotechnology

Talent Development



141

assignment to support 60 startups in China through the EXPAND program

Connect With Us

Are you working on an early-stage innovation that has the potential to transform into the next breakthrough idea or solution? We want to hear from you.

Contact our team in APAC

Submit your proposal to meet with us 1:1

jji.jnj/apac

Subscribe to our e-newsletters

jnjinnovation.com/subscribe

Follow us on WeChat




Visit our website for more information

www.jnjinnovation.com

© Johnson & Johnson Innovation, LLC 2022

Cautions Concerning Forward-Looking Statements

This report contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to new collaborations and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc., Janssen Research & Development, LLC, Johnson & Johnson Innovation, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaborations may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The Janssen Pharmaceutical Companies, Johnson & Johnson Innovation, LLC and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.



Sign up to stay in touch with us

[Subscribe](#)

Approach

Early Innovation Partnerships

Venture capital with JJDC

Incubation with JLABS

Challenges

Connect with Us

Focus

MedTech

Innovative Medicine

Careers

Locations

Sitemap

JNJInnovation



JLABS



[Apply](#)



[JLABS Resident Login](#)

Johnson&Johnson

Visit our parent site [Johnson & Johnson](#)

| Innovation

© Johnson & Johnson and its affiliates 2025. All rights reserved.

Your use of the information on this site is subject to the terms of our [Legal Notice](#). Please see our [Privacy Policy](#), [Cookie Policy](#) and [Do Not Sell or Share My Information](#) form. This site is published by Johnson & Johnson which is solely responsible for its contents. This site is intended for global audiences.